The capital raise removes near-term financing risk but at meaningful dilution. The key catalyst is the Phase 3 APOLLO bitopertin readout in Q4 2026 — success could offset dilution sentiment, while failure would leave the company with excess cash and no near-term commercial product. Monitor for APOLLO topline data and any insider selling post-lockup expiration.
Price Chart
Executive Summary
Disc Medicine completed a $450M upsized public offering of 6M shares at $75/share, raising ~$422.4M net proceeds to extend cash runway into 2030. The company also disclosed preliminary Q3 2026 cash of ~$682.8M, down from $717.7M at Q2 end, reflecting ongoing clinical spend. The offering was priced at a ~5.6% discount to the prior close ($79.48), creating immediate dilution for existing holders, though the capital strengthens the balance sheet ahead of the pivotal Phase 3 APOLLO bitopertin readout in Q4 2026.
Key Financial Metrics
Key Facts
- Priced upsized offering of 6,000,000 shares at $75.00/share, raising $450M gross / ~$422.4M net proceeds
- Underwriters have 30-day option for up to 900,000 additional shares ($52.5M at offering price)
- Preliminary Q3 2026 cash balance ~$682.8M, down from $717.7M at June 30, 2026
- Pro forma cash runway extended into 2030, excluding potential bitopertin revenue
- Offering priced at ~5.6% discount to $79.48 prior close; 6M new shares represent ~15.5% dilution vs 38.7M pre-offering shares outstanding
- Q2 2026 net loss $59.5M on $0 revenue; R&D spend $46.9M, SG&A $18.1M
- Phase 3 APOLLO topline data for bitopertin in EPP expected Q4 2026
Financial Impact
~$450M gross proceeds raised; ~15.5% dilution to existing shareholders; pro forma cash runway extended into 2030
Risk Factors
- Phase 3 APOLLO trial failure would eliminate the near-term commercial catalyst
- Dilution overhang as 6M new shares enter the float
- Cash burn rate of ~$60M/quarter implies ~3 years of runway even after raise
- No approved products or revenue; pre-commercialization costs may increase
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-429105 |
| Document: d457786d8k.htm | 0001193125-26-429105 |
| Document: d457786dex991.htm | 0001193125-26-429105 |
| Document: d457786dex992.htm | 0001193125-26-429105 |
| Document: d457786dex51.htm | 0001193125-26-429105 |
| Document: 0001193125-26-429105-index-headers.html | 0001193125-26-429105 |
| Document: 0001193125-26-429105-index.html | 0001193125-26-429105 |
| Document: 0001193125-26-429105.txt | 0001193125-26-429105 |
| 8-K Data (Synthetic) | 0001193125-26-429105 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $74.95 | awaiting T+20 | — | $74.51 (+0.59%) |
Oct 21, 2026 4d ago | 424B5 | $75.03 | awaiting T+20 | — | $74.51 (+0.69%) |
Oct 21, 2026 4d ago | 144 | $75.03 | awaiting T+20 | — | $74.51 (−0.69%) |
Oct 21, 2026 4d ago | 144 | $75.03 | awaiting T+20 | — | $74.51 (−0.69%) |
Oct 21, 2026 4d ago | 144 | $75.03 | awaiting T+20 | — | $74.51 (−0.69%) |
Oct 20, 2026 5d ago | 144 | $76.00 | awaiting T+20 | — | $74.51 (−1.96%) |
Oct 20, 2026 5d ago | 144 | $76.00 | awaiting T+20 | — | $74.51 (−1.96%) |
Oct 20, 2026 5d ago | 144 | $76.00 | awaiting T+20 | — | $74.51 (−1.96%) |
Oct 19, 2026 6d ago | 424B5 | $79.48 | awaiting T+20 | — | $74.51 (+6.25%) |
Oct 19, 2026 6d ago | 144 | $79.48 | awaiting T+20 | — | $74.51 (−6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers